All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Eqrx Inc., a new venture created to advance fast-follower drugs that founding CEO Alexis Borisy said will be priced "radically lower" than first-in-class medicines, launched with $200 million in series A financing.
Med-tech companies brought in more money than each of the last two years in every type of financing, aside from private placements, with about 11% of the funds flowing into digital health companies. In total, the industry raised $40.67 billion, an increase of 98% over 2018, which logged $20.6 billion and was more in line with the $19.4 billion raised in 2017.
BEIJING – CF Pharmtech Inc., of Suzhou, China, closed a ¥630 million (US$90 million) series E financing round to bring its inhaled respiratory drugs to global markets and replace imports with homegrown products faster.
Artificial intelligence (AI) health care startup Cardiologs Technologies SAS scooped up $15 million in a series A funding round led by Alven Capital Partners. The Paris-based company, which has an artificial intelligence-based platform to quickly diagnose cardiac arrhythmias, plans to use the money to grow its sales and marketing efforts across North America and Europe. The funds will also be used to advance the platform’s capabilities. Also participating in the financing were previous investors Bpifrance, Isai, Kurma Diagnostics, Idinvest Partners and Paris Saclay Seed Fund.
BEIJING – China-U.S. biotech Transcenta Holding Ltd., headquartered in Shanghai and Boston, completed a series B+ financing round to secure $100 million to continue its efforts in developing oncology and bone disorder drugs and to prepare for an IPO.
NBE Therapeutics AG raised $22 million in a series C round to take its first antibody-drug conjugate (ADC), NBE-002, into the clinic. NBE-002, which targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), is in development for both solid tumors and lymphomas
BEIJING – China will kickstart a phase III trial Feb. 3 to determine whether patients with 2019-nCoV can be treated with Gilead Sciences Inc.’s NUC inhibitor,...
HONG KONG – In another example that communication is proving as difficult as containment in the current coronavirus outbreak, China’s state media reported, to...
HONG KONG – A team of researchers at Hong Kong University of Science and Technology (HKUST) claim to have invented the world’s fastest portable 2019-nCoV...
SEATTLE – Tracing the family tree of COVID-19 through its evolving DNA sequence makes it possible to disprove many false claims circulating on social media about...
HONG KONG – As drug developers are racing to find a cure for the new coronavirus, researchers in Hong Kong claim to have made major headway in the development of...
BioWorld Premium
Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.
RSS
